Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b open-label study of lenvatinib plus pembrolizumab in selected solid tumors
jRCT2080223435Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib and pembrolizumab in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EC) and 3 more, sponsored by Eisai Co., Ltd. Started Jan 2017; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)endometrial cancer (EC)transitional cell carcinoma (TCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080223435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223435.